Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07085039 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
A Phase 2 study of Castleman's Disease (CD) and Idiopathic Multicentric Castleman's Disease, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT07085039: Recruiting Phase 2 study of Castleman's Disease (CD) and Idiopathic Multicentric Castleman's Disease, sponsored by University of Pennsylvania.
NCT07085039 is a Phase 2 study of Castleman's Disease (CD) and Idiopathic Multicentric Castleman's Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07085039, a Phase 2 study of Castleman's Disease (CD) and Idiopathic Multicentric Castleman's Disease, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.
Primary Outcome
Clinical Benefit Response (CBR):CBR is defined by improvements in clinical symptoms (fatigue, anorexia, fever and night sweats). Laboratory markers like Hemoglobin levels, weight change and lymph node size are included in the CBR. A CBR is considered positive if there is at least a 25% reduction in the size of the largest lymph node (measured by modified Cheson criteria), a significant improvement in at least one laboratory marker (e.g., hemoglobin), and improvement in at least one clinical symp
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-12-18 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT07085039 shows while recruiting
NCT07085039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Castleman's Disease (CD) appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT07085039 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07085039 about?
NCT07085039 is a clinical study titled "Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease". The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.
What is the current status of trial NCT07085039?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2025-12-18. Estimated completion is 2028-12-31.
What conditions does trial NCT07085039 study?
This clinical trial studies the following conditions: Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease.
What interventions are being tested in trial NCT07085039?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT07085039?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07085039 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07085039's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy